25 Jan 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Meda's Dymista received medical approval in Europe for the treatment of seasonal and perennial allergic rhinitis, via the decentralized registration procedure.
National registration processes, including negotiations regarding pricing and reimbursement, will now follow in each country prior to the launch of the drug starting in 2013.
Dr Anders Lönner, CEO, Meda, said that, "Patients in Europe that suffer from allergic rhinitis will soon have access to a better treatment option than the current standard therapy. The faster and more complete effect offers significant benefit to the growing numbers of patients suffering from this difficult and inhibiting disease."